UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	burden				
hours per response	0.5				

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Re	esponses)														
1. Name and Address of Reporting Person * Ferrara Napoleone				2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O DELMAR PHARMACEUTICALS, INC., SUITE 720-999 WEST BROADWAY			$S, \qquad 0$	3. Date of Earliest Transaction (Month/Day/Year) 04/30/2019							Officer (give ti	le below)	Other (s	pecify below)	
(Street) VANCOUVER, A1 V5Z 1K5			4.	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group FilingCheck Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	LIK, MI VJ	(State)	(Zip)				Table I -	Non-Deriva	ative Securities	Acquired, l	Disposed of	, or Benefic	ially Owned		
1. Title of Securi (Instr. 3)			2. Transaction Date (Month/Day/Year)	(Month/	on Day/	Year)	(Instr. 8) Code	(A) (Ins	or Disposed of tr. 3, 4 and 5) (A) or ount (D)	(D) Owne Transa	ount of Sec d Following action(s) 3 and 4)	urities Bener Reported	Or Fo Di or (I)	wnership orm: Birect (D) Indirect (I	. Nature f Indirect Beneficial Ownership Instr. 4)
Reminder: Repo	ort on a separa	te line for each clas	Table II -	Derivativ	ve Se	curit	ies Acquii	Persons versions this form currently red, Dispose	who respond are not require valid OMB co	red to resp entrol numb cially Owned	ond unles per.			SEC 14	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Underlyi Securities (Instr. 3 and	ng	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(msu. 4)	(IIISU. 4)	
Performance Stock Units	<u>(1)</u>	04/30/2019		D			200,000	<u>(1)</u>	07/07/2022	Common Stock	200,000	\$ 0	0	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Ferrara Napoleone C/O DELMAR PHARMACEUTICALS, INC. SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	X						

Signatures

/s/ Anthony Scott Praill, attorney-in-fact for Napoleone Ferrara	05/01/2019	
-**Signature of Reporting Person	Date	

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.